111,750 Shares in Pfizer Inc. $PFE Bought by Black Swift Group LLC

Black Swift Group LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 111,750 shares of the biopharmaceutical company’s stock, valued at approximately $2,847,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the third quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the 2nd quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd bought a new position in shares of Pfizer during the 2nd quarter worth approximately $33,000. Finally, True Wealth Design LLC lifted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Royal Bank Of Canada began coverage on Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Trading Up 1.7%

Shares of Pfizer stock opened at $27.07 on Friday. The firm’s 50 day simple moving average is $26.30 and its two-hundred day simple moving average is $25.47. The firm has a market capitalization of $153.93 billion, a price-to-earnings ratio of 19.90 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, January 23rd were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date was Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.